Abstract
Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / pharmacokinetics
-
Anti-Inflammatory Agents / pharmacology
-
Anti-Inflammatory Agents / therapeutic use*
-
Choroidal Neovascularization / drug therapy*
-
Disease Models, Animal
-
Drug Delivery Systems*
-
Drug Evaluation, Preclinical
-
Drug Implants
-
Fluocinolone Acetonide / administration & dosage
-
Fluocinolone Acetonide / pharmacokinetics
-
Fluocinolone Acetonide / pharmacology
-
Fluocinolone Acetonide / therapeutic use*
-
Humans
-
Macular Edema / drug therapy*
-
Patents as Topic
-
Randomized Controlled Trials as Topic
-
Structure-Activity Relationship
-
Uveitis, Posterior / drug therapy*
Substances
-
Anti-Inflammatory Agents
-
Drug Implants
-
Fluocinolone Acetonide